• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BECTON, DICKINSON & CO. (SPARKS) BD BBL¿ CHOCOLATE II AGAR (GC II AGAR WITH HEMOGLOBIN AND ISOVITALEX¿); CULTURE MEDIA, FOR ISOLATION OF PATHOGENIC NEISSERIA

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BECTON, DICKINSON & CO. (SPARKS) BD BBL¿ CHOCOLATE II AGAR (GC II AGAR WITH HEMOGLOBIN AND ISOVITALEX¿); CULTURE MEDIA, FOR ISOLATION OF PATHOGENIC NEISSERIA Back to Search Results
Model Number 221267
Device Problem Incorrect, Inadequate or Imprecise Result or Readings (1535)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 10/23/2022
Event Type  malfunction  
Manufacturer Narrative
A device evaluation and/or device history review is anticipated but is not complete.Upon completion, a supplemental report will be filed.
 
Event Description
It was reported that while using bd bbl¿ chocolate ii agar (gc ii agar with hemoglobin and isovitalex) failed growth promotion occurred.The following information was provided by the initial reporter: "customer reports haemophilus failed to grow on 221261 - lot #2228641."hazard, injury or erroneous results? no.Hazard, injury or erroneous results details.".
 
Manufacturer Narrative
H.6 investigation summary: during manufacturing of material 221267, media is formulated and sent through a high temperature short time sterilizer to remove bioburden.The petri dishes are subjected to uv radiation to decrease bioburden.The petri dishes are filled in a positive pressure hepa filtered environment.The filled plates are cooled and immediately wrapped into sleeves to decrease the introduction of microbes.Sleeves are then packaged into cartons and then transferred to a refrigerated truck (2 to 8 degrees c) for shipment to the distributor.Bd distributors are provided with the storage guidelines for the shipping and handling of bd media of 2 to 8 degrees c in a dark place.The batch history record for batch 2228641 was satisfactory and no quality notifications were generated during manufacturing and inspection.All batches are tested prior to release and results reported on the certificate of analysis which can be obtained at www.Bd.Com/regdocs.Chocolate ii agar is stability tested biennially for biological performance to ensure satisfactory performance throughout shelf life with the organisms that are reported on the certificate of analysis.All performance testing on this batch was satisfactory at the time of release.The complaint history was reviewed, and no other complaints have been taken on batch 2228641 for performance.Retention samples from batch 2228641 were not available for investigation.Ninety-nine plates from batch 2228641 were returned as 10 sleeves (1 opened, 9 unopened) in a 100pack carton shipped in a box with paper padding (carton number 0269, time stamps 1736 and 1737).Returned samples were tested with haemophilus influenzae atcc 10211 and haemophilus parainfluenzae atcc 51505 per the standard performance protocol for material 221267.Both atcc 10211 and atcc 51505 had heavy growth at one day incubation.Amount of growth and colony size was compared to the chocolate ii agar control and growth on batch 2228641 was satisfactory.One photo also was received for investigation.The photo shows the bottom of a plate from batch 2228641 (time stamp 1736).H3 other text : see h.10.
 
Event Description
It was reported that while using bd bbl¿ chocolate ii agar (gc ii agar with hemoglobin and isovitalex¿) failed growth promotion occurred.The following information was provided by the initial reporter: "customer reports haemophilus failed to grow on 221261 - lot #2228641."hazard, injury or erroneous results? no.Hazard, injury or erroneous results details ".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BD BBL¿ CHOCOLATE II AGAR (GC II AGAR WITH HEMOGLOBIN AND ISOVITALEX¿)
Type of Device
CULTURE MEDIA, FOR ISOLATION OF PATHOGENIC NEISSERIA
Manufacturer (Section D)
BECTON, DICKINSON & CO. (SPARKS)
7 loveton circle
sparks MD 21152
Manufacturer (Section G)
BECTON, DICKINSON & CO. (SPARKS)
7 loveton circle
sparks MD 21152
Manufacturer Contact
phillip emmert
9450 south state street
sandy, UT 84070
8015296192
MDR Report Key15757235
MDR Text Key305243483
Report Number1119779-2022-01369
Device Sequence Number1
Product Code JTY
UDI-Device Identifier10382902212673
UDI-Public10382902212673
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
NA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,User Facility
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 04/14/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/08/2022
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Other
Device Expiration Date12/12/2022
Device Model Number221267
Device Catalogue Number221267
Device Lot Number2228641
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received04/14/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured08/16/2022
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-